181 related articles for article (PubMed ID: 38236288)
21. Integrating Postradiotherapy MRI-Detected Lymph Node Necrosis and Pre- and Posttreatment Epstein-Barr Virus-DNA for Risk Stratification in Nasopharyngeal Carcinoma.
Cao D; Li S; Li H; Liu L; Wang X; Quan T
J Magn Reson Imaging; 2023 Jul; 58(1):108-119. PubMed ID: 36326089
[TBL] [Abstract][Full Text] [Related]
22. Two web-based dynamically interactive nomograms and risk stratification systems for predicting survival outcomes and guiding treatment in non-metastatic nasopharyngeal carcinoma.
Zuo H; Li MM
J Cancer Res Clin Oncol; 2023 Nov; 149(17):15969-15987. PubMed ID: 37684510
[TBL] [Abstract][Full Text] [Related]
23. Prognostic efficacy of the combination of the pretreatment systemic Immune-Inflammation Index and Epstein-Barr virus DNA status in locally advanced Nasopharyngeal Carcinoma Patients.
Xiong Y; Shi LL; Zhu LS; Ding Q; Ba L; Peng G
J Cancer; 2021; 12(8):2275-2284. PubMed ID: 33758605
[No Abstract] [Full Text] [Related]
24. Maximal standard uptake values of
Sun XS; Liang YJ; Liu SL; Chen QY; Guo SS; Wen YF; Liu LT; Xie HJ; Tang QN; Li XY; Yan JJ; Tang LQ; Mai HQ
BMC Cancer; 2019 Sep; 19(1):908. PubMed ID: 31511059
[TBL] [Abstract][Full Text] [Related]
25. Circulating Epstein-Barr virus microRNAs BART7-3p and BART13-3p as novel biomarkers in nasopharyngeal carcinoma.
Lu T; Guo Q; Lin K; Chen H; Chen Y; Xu Y; Lin C; Su Y; Chen Y; Chen M; Zheng Y; Ye Y; Lin S; Zong J; Pan J
Cancer Sci; 2020 May; 111(5):1711-1723. PubMed ID: 32155300
[TBL] [Abstract][Full Text] [Related]
26. Significance of Dynamic Changes of VCA-IgA Levels in Pre- and Post-treatment Plasma of Patients with Nasopharyngeal Carcinoma: Development of a Clinically-Oriented Model.
Mao M; Sheng H; Tian B; Chi P; Huang K; Li H; Liu W
Adv Ther; 2023 May; 40(5):2426-2438. PubMed ID: 36964411
[TBL] [Abstract][Full Text] [Related]
27. Immunotherapeutic approaches in nasopharyngeal carcinoma.
Chow JC; Ngan RK; Cheung KM; Cho WC
Expert Opin Biol Ther; 2019 Nov; 19(11):1165-1172. PubMed ID: 31361154
[No Abstract] [Full Text] [Related]
28. The diagnostic and prognostic values of plasma Epstein-Barr virus DNA for residual cervical lymphadenopathy in nasopharyngeal carcinoma patients: a retrospective study.
Liu SL; Sun XS; Li XY; Tang LQ; Chen QY; Lin HX; Liang YJ; Yan JJ; Lin C; Guo SS; Liu LT; Li Y; Xie HJ; Tang QN; Liang H; Guo L; Mai HQ
Cancer Commun (Lond); 2019 Mar; 39(1):14. PubMed ID: 30925939
[TBL] [Abstract][Full Text] [Related]
29. Targeting Epstein-Barr virus oncoprotein LMP1-mediated high oxidative stress suppresses EBV lytic reactivation and sensitizes tumors to radiation therapy.
Hu J; Li Y; Li H; Shi F; Xie L; Zhao L; Tang M; Luo X; Jia W; Fan J; Zhou J; Gao Q; Qiu S; Wu W; Zhang X; Liao W; Bode AM; Cao Y
Theranostics; 2020; 10(26):11921-11937. PubMed ID: 33204320
[TBL] [Abstract][Full Text] [Related]
30. Epstein-Barr virus DNA change level combined with tumor volume reduction ratio after inductive chemotherapy as a better prognostic predictor in locally advanced nasopharyngeal carcinoma.
Xiang ZZ; He T; Zeng YY; Liu F; Shao BF; Yang T; Ma JC; Wang XR; Yu ST; Liu L
Cancer Med; 2023 Jan; 12(2):1102-1113. PubMed ID: 35852473
[TBL] [Abstract][Full Text] [Related]
31. Prognostic value of circulating Epstein-Barr virus DNA level post-induction chemotherapy for patients with nasopharyngeal carcinoma: A recursive partitioning risk stratification analysis.
Kong FF; Pan GS; Du CR; Ni MS; Zhai RP; He XY; Shen CY; Lu XG; Hu CS; Ying HM
Radiother Oncol; 2023 Aug; 185():109721. PubMed ID: 37244356
[TBL] [Abstract][Full Text] [Related]
32. Prognostic significance of circulating CD19+ B lymphocytes in EBV-associated nasopharyngeal carcinoma.
Xu T; Huang Z; Su B; Wang S; Wang D; Wang C; Wei W; Jiang J; Zhang G; Yang H; Hu W
Med Oncol; 2014 Oct; 31(10):198. PubMed ID: 25182703
[TBL] [Abstract][Full Text] [Related]
33. Expression of Immune Checkpoint Regulators, Cytotoxic T-Lymphocyte Antigen-4, and Programmed Death-Ligand 1 in Epstein-Barr Virus-associated Nasopharyngeal Carcinoma.
Ahmed MM; Gebriel MG; Morad EA; Saber IM; Elwan A; Salah M; Fakhr AE; Shalaby AM; Alabiad MA
Appl Immunohistochem Mol Morphol; 2021 Jul; 29(6):401-408. PubMed ID: 33480605
[TBL] [Abstract][Full Text] [Related]
34. Combination of Tumor Volume and Epstein-Barr Virus DNA Improved Prognostic Stratification of Stage II Nasopharyngeal Carcinoma in the Intensity Modulated Radiotherapy Era: A Large-Scale Cohort Study.
Chen QY; Guo SY; Tang LQ; Lu TY; Chen BL; Zhong QY; Zou MS; Tang QN; Chen WH; Guo SS; Liu LT; Li Y; Guo L; Mo HY; Sun R; Luo DH; Zhao C; Cao KJ; Qian CN; Guo X; Zeng MS; Mai HQ
Cancer Res Treat; 2018 Jul; 50(3):861-871. PubMed ID: 28903550
[TBL] [Abstract][Full Text] [Related]
35. The Dynamic Change in Plasma Epstein-Barr Virus DNA Load over a Long-Term Follow-Up Period Predicts Prognosis in Nasopharyngeal Carcinoma.
Gihbid A; Benzeid R; Faouzi A; El Alami I; Tawfiq N; Benchakroun N; Bendahhou K; Benider A; Guensi A; Khaali W; Chaoui I; El Mzibri M; Cadi R; Khyatti M
Viruses; 2022 Dec; 15(1):. PubMed ID: 36680107
[TBL] [Abstract][Full Text] [Related]
36. Combining pretreatment plasma Epstein-Barr virus DNA level and cervical node necrosis improves prognostic stratification in patients with nasopharyngeal carcinoma: A cohort study.
Du YY; Luo DH; Sun XS; Tang LQ; Mai HQ; Chen QY; Zhong JH; Mai DM; Zhang WR; Chen WH; Mo HY
Cancer Med; 2019 Nov; 8(16):6841-6852. PubMed ID: 31513364
[TBL] [Abstract][Full Text] [Related]
37. A multidimensional nomogram combining overall stage, dose volume histogram parameters and radiomics to predict progression-free survival in patients with locoregionally advanced nasopharyngeal carcinoma.
Yang K; Tian J; Zhang B; Li M; Xie W; Zou Y; Tan Q; Liu L; Zhu J; Shou A; Li G
Oral Oncol; 2019 Nov; 98():85-91. PubMed ID: 31569054
[TBL] [Abstract][Full Text] [Related]
38. Predicting Progression-Free Survival Using MRI-Based Radiomics for Patients With Nonmetastatic Nasopharyngeal Carcinoma.
Shen H; Wang Y; Liu D; Lv R; Huang Y; Peng C; Jiang S; Wang Y; He Y; Lan X; Huang H; Sun J; Zhang J
Front Oncol; 2020; 10():618. PubMed ID: 32477932
[No Abstract] [Full Text] [Related]
39. Identifying distinct risks of treatment failure in nasopharyngeal carcinoma: Study based on the dynamic changes in peripheral blood lymphocytes, monocytes, N classification, and plasma Epstein-Barr virus DNA.
Liu LT; Liang YJ; Guo SS; Xie Y; Jia GD; Wen DX; Tang LQ; Chen QY; Mai HQ
Head Neck; 2022 Jan; 44(1):34-45. PubMed ID: 34636116
[TBL] [Abstract][Full Text] [Related]
40. Integrating pretreatment MRI-detected nodal features and Epstein-Barr virus DNA to identify optimal candidates for intensity-modulated radiotherapy alone in patients with stage II nasopharyngeal carcinoma.
Guo J; He Y; Lin C; Jiang Q; Xing HW; Zhang YC; Shen GZ; Lin HX; Guo L; Yang Q
Oral Oncol; 2023 Nov; 146():106574. PubMed ID: 37741017
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
